What is the convatec group?
ConvaTec Group Plc is a major multinational medical products and technologies enterprise headquartered in London, England, specializing in solutions for the management of chronic medical conditions. Listed on the London Stock Exchange and a constituent of the FTSE 100 Index, ConvaTec operates across four primary business segments: advanced wound care, ostomy care, continence care, and infusion care, providing critical medical devices and patient support services to healthcare providers and home care markets globally.
Related FAQs
Convatec Group Plc is a major medical products and technologies company, and its "worth" is measured by its market capitalization on the London Stock Exchange. As of August 2, 2026, the company has a market capitalization of approximately £4.
ConvaTec Group PLC operates as an independent, publicly traded global medical products and technologies company listed on the London Stock Exchange.
As of late July 2026, the Global X ClimateTech ETF (CTEC) is generally categorized as a "Sell" based on various quantitative stock scoring models.
Yes, Converse is a significant supporter of the LGBTQ+ community.
Market analysts evaluate various equities designated by the ticker CTEC by reviewing quarterly financial results, industry tailwinds, and corporate guidance metrics.
ConvaTec Group PLC is a prominent, multi-billion-dollar global medical products and technologies enterprise listed on the London Stock Exchange and recognized as a world leader in chronic care solutions.
ConvaTec generates the vast majority of its revenue—approximately 97%—through the ongoing sale of medical products designed for the treatment of chronic conditions, such as colostomy bags and insulin pumps.
Convatec features a comprehensive medical technology catalog centered around advanced wound care, ostomy care, continence care, and infusion devices.
Core & Main, Inc. employs approximately five thousand one hundred to five thousand six hundred associates specializing in the distribution of water, wastewater, storm drainage, and fire protection products. Headquartered in St.
ConvaTec Group PLC trades on the London Stock Exchange under the ticker CTEC at approximately 224.00 pence per share.
Convatec is a global medical products and technologies company that focuses on the development and manufacturing of medical solutions for chronic conditions.
Convatec Group PLC operates as a global public limited medical products and technologies enterprise headquartered in London, England, and is a constituent of the FTSE 100 Index.
Yes, Convatec Group PLC pays dividends on a biannual basis. As of mid-2026, the company maintains a dividend yield of approximately 2.47%.
CTEC is the ticker symbol for CleanTech Lithium, a company focused on the exploration and development of sustainable lithium assets in Chile.
ConvaTec Group earns a strong reputation within the global medical technology sector, praised for its innovative healthcare solutions that significantly improve clinical outcomes and quality of life for patients managing chronic conditions.
ConvaTec Group PLC, a major global medical products and technologies company specializing in wound care, ostomy care, continence, and critical care devices, officially completed its initial public offering on the London Stock Exchange in October 2016...
Financial analysts frequently position ConvaTec Group as an attractive stock purchase due to its defensive healthcare profile, predictable recurring revenues from consumable medical supplies, and visible organic growth drivers.
CoreCivic, the largest private prison company in the United States, generates its income primarily through government contracts.
ConvaTec Group PLC trades on the London Stock Exchange under ticker CTEC near 224.00 pence per share.
Convatec is a prominent global medical products and technologies company focused on therapies for the management of chronic conditions.
ConvaTec Group PLC is not currently backed by private equity firms, as it operates as an independent, publicly traded enterprise listed on the London Stock Exchange and included within the FTSE 100 index.
Equity research analysts covering ConvaTec Group overwhelmingly rate the stock as a strong buy, driven by consistent organic revenue acceleration, expanding profit margins, and robust demand across its specialized medical segments like infusion care.